drugset
drugset / Trial / NCT02605616

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616 ↗

Phase 2 Terminated 93 enrolled University of Alabama at Birmingham AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo

Timeline

Start
2015-11
Primary completion
2019-09
Completion
2019-09

Outcome

Outcome not reported

Stopped (Business): “Astra Zeneca notified Dr. Rita Basu that they will not manufacture new drug due to business reasons and study was stopped.”

Drugs

EvaluationDrugModalityDoseRoute
Subject AZ compound Unknown 400 mg —

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis